Stock DNA
Pharmaceuticals & Biotechnology
INR 25,120 Cr ()
89.00
36
0.10%
0.00
0.00%
19.83
Total Returns (Price + Dividend) 
Rubicon Research for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News
Announcements 
Closure of Trading Window
28-Sep-2026 | Source : BSEIntimation of Trading Window Closure
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
29-Aug-2026 | Source : BSEThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for General Atlantic Singapore RR Pte Ltd
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
27-Aug-2026 | Source : BSEThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for General Atlantic Singapore RR Pte Ltd
Corporate Actions 
No Upcoming Board Meetings
Rubicon Research Ltd has declared 150% dividend, ex-date: 07 Aug 26
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 14 Schemes (7.23%)
Held by 39 FIIs (7.52%)
General Atlantic Singapore Rr Pte Ltd (35.83%)
Shivanand Shankar Mankekar Huf (13.52%)
3.46%
Quarterly Results Snapshot (Standalone) - Jun'26 - QoQ
QoQ Growth in quarter ended Jun 2026 is 9.71% vs 29.22% in Mar 2026
QoQ Growth in quarter ended Jun 2026 is 17.75% vs 88.33% in Mar 2026
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 36.57% vs 50.40% in Mar 2025
YoY Growth in year ended Mar 2026 is 83.64% vs 47.63% in Mar 2025